Bissig, M., Hagenbuch, B., Stieger, B., Koller, T
The efficacy question no press release answers: Oral small molecules historically trail injectable biologics on PASI response
This is an FDA-approved, in-office topical treatment that takes approximately 30 minutes and is performed weekly for 5-6 consecutive treatments
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
M.ChungK.LiangC
Heres a bit more about why we prefer Limitless Life : Commitment to Quality Control: Limitless Life works with three independent laboratories that conduct testing on each batch to ensure product quality, purity, and potency